Scientech Research LLC Boosts Stake in Medpace Holdings, Inc. $MEDP

Scientech Research LLC grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 115.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 3,043 shares of the company's stock after acquiring an additional 1,630 shares during the period. Scientech Research LLC's holdings in Medpace were worth $927,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Whittier Trust Co. grew its holdings in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares during the period. Benjamin Edwards Inc. grew its holdings in shares of Medpace by 3.1% during the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after acquiring an additional 36 shares during the period. Assetmark Inc. grew its holdings in shares of Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Medpace by 6.4% during the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after acquiring an additional 47 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after acquiring an additional 48 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Trading Up 1.0%

Shares of MEDP opened at $486.98 on Monday. The business's fifty day simple moving average is $412.68 and its two-hundred day simple moving average is $344.18. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30. The company has a market cap of $13.68 billion, a price-to-earnings ratio of 36.21, a P/E/G ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period last year, the business posted $2.75 EPS. The company's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer directly owned 925,799 shares in the company, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total value of $772,896.48. Following the sale, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 161,266 shares of company stock worth $74,111,427. Insiders own 20.30% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on MEDP shares. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and upped their target price for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. William Blair restated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Barclays upped their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and upped their price target for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, Robert W. Baird upped their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Reduce" and an average price target of $412.73.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.